Kura Oncology KURA Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kura Oncology's change in deferred revenue?
- Kura Oncology (KURA) reported change in deferred revenue of -$9.44M in Q1 2026.
- How has Kura Oncology's change in deferred revenue changed year-over-year?
- Kura Oncology's change in deferred revenue decreased by 127.3% year-over-year, from $34.59M to -$9.44M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.